<DOC>
	<DOCNO>NCT00047294</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Thalidomide celecoxib may stop growth tumor cell stop blood flow tumor may increase effectiveness temozolomide make tumor cell sensitive drug . PURPOSE : Phase II trial study effectiveness combine temozolomide , thalidomide , celecoxib follow radiation therapy treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Temozolomide , Thalidomide , Celecoxib Following Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy adjuvant temozolomide , thalidomide , celecoxib radiotherapy , term time tumor progression overall survival , patient newly diagnose glioblastoma multiforme . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive oral temozolomide daily day 1-5 oral thalidomide daily oral celecoxib twice daily day 1-28 . Treatment repeat every 28 day 24 course absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 55 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial glioblastoma multiforme gliosarcoma Completed standard external beam radiotherapy within past 5 week Stable disease MRI CT scan PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy More 4 month Hematopoietic Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 No history bleed disorder Hepatic Bilirubin le 1.5 mg/dL SGPT le 2.5 time normal Alkaline phosphatase less 2.5 time normal Renal BUN less 1.5 time upper limit normal ( ULN ) OR Creatinine le 1.5 time ULN Cardiovascular No deep vein thrombosis within past 3 week ( must clinically stable ) Pulmonary No pulmonary embolism within past 3 week ( must clinically stable ) Other Must participate System Thalidomide Education Prescribing Safety program No peripheral neuropathy grade 2 great No active infection No concurrent illness may obscure toxicity dangerously alter drug metabolism No serious concurrent illness No malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use 2 form effective contraception 1 month , , 1 month study PRIOR CONCURRENT THERAPY : Biologic therapy No prior thalidomide No concurrent immunotherapy No concurrent prophylactic filgrastim ( GCSF ) Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy No concurrent hormonal therapy Concurrent corticosteroid must stable decrease dose past 7 day Radiotherapy See Disease Characteristics No concurrent radiotherapy Surgery No concurrent surgery Other No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>